155 related articles for article (PubMed ID: 34369236)
1. Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer.
Yan M; Han M; Yang X; Shen R; Wang H; Zhang L; Xia S; Yang P; Zhai G; Shao Q
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1905-1915. PubMed ID: 34369236
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway.
Liu L; Liu FB; Huang M; Xie K; Xie QS; Liu CH; Shen MJ; Huang Q
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):580-586. PubMed ID: 30898507
[TBL] [Abstract][Full Text] [Related]
3. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
5. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes.
Xiang M; Birkbak NJ; Vafaizadeh V; Walker SR; Yeh JE; Liu S; Kroll Y; Boldin M; Taganov K; Groner B; Richardson AL; Frank DA
Sci Signal; 2014 Jan; 7(310):ra11. PubMed ID: 24473196
[TBL] [Abstract][Full Text] [Related]
6. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
8. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA EGFR-AS1 in colorectal cancer: potential role in tumorigenesis and survival via miRNA-133b sponge and EGFR/STAT3 axis regulation.
Atef MM; Amer AI; Hafez YM; Elsebaey MA; Saber SA; Abd El-Khalik SR
Br J Biomed Sci; 2021 Jul; 78(3):122-129. PubMed ID: 33211633
[TBL] [Abstract][Full Text] [Related]
10. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
11. Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells.
Wang HC; Yeh HH; Huang WL; Lin CC; Su WP; Chen HH; Lai WW; Su WC
Mol Endocrinol; 2011 Jul; 25(7):1145-58. PubMed ID: 21546410
[TBL] [Abstract][Full Text] [Related]
12. MiR-203 regulates proliferation and apoptosis of ovarian cancer cells by targeting SOCS3.
Liu HP; Zhang Y; Liu ZT; Qi H; Zheng XM; Qi LH; Wang JY
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9286-9294. PubMed ID: 31773696
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
14. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
15. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
16. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Edmonds C; Hagan S; Gallagher-Colombo SM; Busch TM; Cengel KA
Cancer Biol Ther; 2012 Dec; 13(14):1463-70. PubMed ID: 22986230
[TBL] [Abstract][Full Text] [Related]
18. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
19. Suppression of ovarian cancer by low-intensity ultrasound through depletion of IL-6/STAT3 inflammatory pathway-maintained cancer stemness.
Gong T; Zhang P; Jia L; Pan Y
Biochem Biophys Res Commun; 2020 Jun; 526(3):820-826. PubMed ID: 32273089
[TBL] [Abstract][Full Text] [Related]
20. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.
Jiang B; Zhu SJ; Xiao SS; Xue M
Inflammation; 2019 Oct; 42(5):1517-1529. PubMed ID: 31049770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
